{"product_id":"drug-utilization-research-isbn-9781119911654","title":"Drug Utilization Research","description":"\u003cp\u003e\u003cb\u003eTowards a better understanding of how medicines are used in society\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eDrug Utilization Research (DUR) is a discipline which combines aspects of pharmacotherapy, epidemiology, and health services research into an interdisciplinary set of methods for analyzing and assessing the prescribing, dispensing and consumption of medicines. It combines both qualitative and quantitative approaches to facilitate the safe and effective use of pharmaceuticals. \u003ci\u003eDrug Utilization Research: Methods and Applications\u003c\/i\u003e provides a comprehensive introduction to this discipline, prepared by an international team of authors with broad experience in numerous fields. Now reorganized and updated to reflect the latest research and global challenges, it is an indispensable resource for understanding the use of pharmaceuticals. \u003c\/p\u003e\u003cp\u003eReaders of the second edition of \u003ci\u003eDrug Utilization Research\u003c\/i\u003e will find: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eNew chapters on methods, including more hands-on guidance on how to plan and conduct different types of drug utilization\u003c\/li\u003e\n\u003cli\u003eA section on specific applications in areas such as psychotropics, opioids, cancer drugs, antibacterials, and cardiovascular drugs\u003c\/li\u003e\n\u003cli\u003eA new section with case studies illustrating applications of DUR in different continents\u003c\/li\u003e\n\u003cli\u003eDetailed treatment of subjects including DUR and health policy, DUR in specific populations, and many more\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003e\u003ci\u003eDrug Utilization Research\u003c\/i\u003e is ideal for epidemiologists, pharmacists, physicians, nurses and others interested in drug use and its outcomes. \u003c\/p\u003e\u003cp\u003eList of contributors ix\u003c\/p\u003e \u003cp\u003ePreface to the second edition xvii\u003c\/p\u003e \u003cp\u003eAcknowledgements xix\u003c\/p\u003e \u003cp\u003eAbout the companion website xxiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Introduction to drug utilization research 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction to drug utilization research 3\u003cbr\u003e\u003ci\u003eBjörn Wettermark, Monique Elseviers, Tanja Mueller, Anna Birna Almarsdottir, Ria Benkö, Marion Bennie, Irina Iaru, Katarina Gvozdanovic, Mikael Hoffmann, Verica Ivanovska, Seán MacBride-Stewart, Elisabetta Poluzzi, Lisa G. Pont, Hege Salvesen Blix, Gabriel Sanfelix-Gimeno, Gisbert W. Selke, Katja Taxis, Ana Tomas Petrovic, Indre Treciokiene, and Sabine Vogler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Methodology of drug utilization research 15\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Research methods in drug utilization research 17\u003cbr\u003e\u003ci\u003eBjörn Wettermark, Indre Treciokiene, Sofia Kälvemark Sporrong, and Louise C. Druedahl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.2 Qualitative methods in drug utilization research 25\u003cbr\u003e\u003ci\u003eLouise C. Druedahl and Sofia Kälvemark Sporrong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.3 Quantitative studies in drug utilization research 41\u003cbr\u003e\u003ci\u003eBjörn Wettermark, Monique Elseviers, and Cristina Mihaela Ghiucic\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.4 Descriptive studies in drug utilization research 51\u003cbr\u003e\u003ci\u003eCristina Mihaela Ghiciuc, Indre Treciokiene, Björn Wettermark, and Monique Elseviers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.5 Analytical studies in drug utilization research 63\u003cbr\u003e\u003ci\u003ePer-Jostein Samuelsen, Björn Wettermark, and Monique Elseviers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.6 Intervention studies in drug utilisation research 73\u003cbr\u003e\u003ci\u003eTanja Mueller, Giampiero Mazzaglia, and Carlos E. Durán\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.7 Statistics in drug utilization research 82\u003cbr\u003e\u003ci\u003eMonique Elseviers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.8 Primary drug utilization data 95\u003cbr\u003e\u003ci\u003eTatiana Chama Borges Luz and Evalill Nilsson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.9 Secondary drug utilization data 104\u003cbr\u003e\u003ci\u003eMohammadhossein Hajiebrahimi, Lisa G. Pont, and Kristina Garuoliene\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.10 Classification systems in drug utilization 115\u003cbr\u003e\u003ci\u003eHege Salvesen Blix, Stuart McTaggart, and Robert Vander Stichele\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.11 Measuring volumes in drug utilization 126\u003cbr\u003e\u003ci\u003eHege Salvesen Blix and Mikael Hoffmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.12 Measuring price and expenditure in drug utilization 137\u003cbr\u003e\u003ci\u003eSabine Vogler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.13 Aggregate-level drug utilization analyses 148\u003cbr\u003e\u003ci\u003eIndre Treciokiene and Claudia Garcia Serpa Osorio-de-Castro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.14 Individual-level drug utilization analyses 158\u003cbr\u003e\u003ci\u003eLotte Rasmussen, Björn Wettermark, Mikael Hoffmann, and Douglas Steinke\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.15 Multilevel analyses in drug utilization research 169\u003cbr\u003e\u003ci\u003eJuan Merlo and George Leckie\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.16 Visualization of drug utilization data 188\u003cbr\u003e\u003ci\u003eMaria Matuz, Ria Benko, and Mikael Hoffmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.17 Artificial intelligence and machine learning in drug utilization research 205\u003cbr\u003e\u003ci\u003eMaurizio Sessa, Saeed Shakibfar, Morten Andersen, and Jing Zhao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.18 Ethics in drug utilization research 215\u003cbr\u003e\u003ci\u003eIndre Treciokiene, Sofia Kälvemark Sporrong, Björn Wettermark, and Louise C. Druedahl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Applied drug utilization research 223\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3.1 Drug utilization research and health policy 225\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1.1 Pharmaceutical policy and drug utilization: Definitions, concepts, and taxonomies 225\u003cbr\u003e\u003ci\u003eSabine Vogler and Anna Birna Almarsdóttir\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1.2 Managed introduction of new medicines in healthcare systems 233\u003cbr\u003e\u003ci\u003eIrina Iaru and Sabine Vogler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1.3 Promoting appropriate use of medicines in a healthcare system 248\u003cbr\u003e\u003ci\u003eMarion Bennie, Amanj Kurdi, and Yared Santa-Ana-Téllez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3.2 Comparative drug utilization research 258\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.2.1 Introduction to comparative drug utilization research 258\u003cbr\u003e\u003ci\u003eSeán MacBride-Stewart and Ana Tomas Petrovic\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.2.2 Comparison of drug utilization across countries 260\u003cbr\u003e\u003ci\u003eYared Santa-Ana Tellez and Monique Elseviers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.2.3 Comparative drug utilization research comparing regions within countries 271\u003cbr\u003e\u003ci\u003eSeán MacBride-Stewart\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.2.4 Comparison of drug utilization across different prescribers and different health care settings 280\u003cbr\u003e\u003ci\u003eSeán MacBride-Stewart, Ksenia Zagorodnikova, and Irene Langner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.2.5 Comparative drug utilization research comparing different patients 292\u003cbr\u003e\u003ci\u003eAna Tomas Petrovic and Mia von Euler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3.3 Drug utilization research in specific populations 303\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.3.1 Drug utilization in pregnant women 303\u003cbr\u003e\u003ci\u003eHedvig Nordeng and Marleen van Gelder\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.3.2 Drug utilization in the paediatric population 314\u003cbr\u003e\u003ci\u003eAntonio Clavenna and Ingvild Odsbu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.3.3 Drug utilization in older people 321\u003cbr\u003e\u003ci\u003ePetra Denig and Katharina Schmidt-Mende\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3.4 Drug utilization research in specific therapeutic areas 331\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.4.1 Introduction to methodological issues in specific therapeutic areas 331\u003c\/p\u003e \u003cp\u003e3.4.2 Drug utilization research on cardiovascular medicines 332\u003cbr\u003e\u003ci\u003eElisabetta Poluzzi, Ana Tomas Petrovic, and Björn Wettermark\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.4.3 Drug utilization research on antibacterials 342\u003cbr\u003e\u003ci\u003eRia Benko and Samuel Coenen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.4.4 Drugs utilization research in specific therapeutic areas - opioids 352\u003cbr\u003e\u003ci\u003eAleksi Hamina, Svetlana Skurtveit, and Mikael Hoffmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.4.5 Drug utilization research on selected psychotropics 363\u003cbr\u003e\u003ci\u003eJonathan Brett and Helga Zoega\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.4.6 Drug utilization research in the area of cancer drugs 373\u003cbr\u003e\u003ci\u003eTanja Mueller and Mikael Hoffmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3.5 Adherence and drug utilization research 381\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.5.1 Introduction to medication adherence research 381\u003cbr\u003e\u003ci\u003eBernard Vrijens\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.5.2 Assessment of medication adherence in field research 387\u003cbr\u003e\u003ci\u003eMonique Elseviers and Bernard Vrijens\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.5.3 Assessment of medication adherence in databases 397\u003cbr\u003e\u003ci\u003eGabriel Sanfélix Gimeno and Tanja Mueller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.5.4 Interventions to improve medication adherence 406\u003cbr\u003e\u003ci\u003eCatherine Goetzinger and Marie P. Schneider\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.5.5 Digital tools and medication adherence 419\u003cbr\u003e\u003ci\u003eAlexandra L. Dima, Urska Nabergoj-Makovec, and Job F.M. van Boven\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3.6 The role of drug utilization in the broader field of health research 428\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.6.1 Risk management and drug utilization research 428\u003cbr\u003e\u003ci\u003eGiampiero Mazzaglia, Ippazio Cosimo Antonazzo, and Peter Mol\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.6.2 Pharmacovigilance and drug utilization research 437\u003cbr\u003e\u003ci\u003eKatarina Gvozdanovic, Bernard Begauld, and Emanuel Raschi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.6.3 The role of drug utilization in outcomes research 445\u003cbr\u003e\u003ci\u003eHenrik Toft Sørensen, Gianluca Trifirò, and Evalill Nilsson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.6.4 Pharmacoeconomics and drug utilization research 456\u003cbr\u003e\u003ci\u003eCara Usher, Kathleen Bennett, Lorenzo G. Mantovani, and Dyfrig Hughes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.6.5 The environment and drug utilisation research 464\u003cbr\u003e\u003ci\u003eMarmar Nekoro, Johanna Villén, and Ana Tomas Petrovic\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3.7 Assessment and improvement of the quality of medicine use 482\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.7.1 Defining the quality of medicines use 482\u003cbr\u003e\u003ci\u003eSeán MacBride-Stewart\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.7.2 Assessing the quality of medication use 488\u003cbr\u003e\u003ci\u003ePetra Denig, Björn Wettermark, and Wade Thompson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.7.3 Challenges in the quality of medicine use 498\u003cbr\u003e\u003ci\u003eKatja Taxis and Carl Llor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.7.4 Development and evaluation of interventions to improve the quality of medicine use 505\u003cbr\u003e\u003ci\u003eSeán MacBride-Stewart and Katja Taxis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.7.5 Implementation of interventions to enhance quality use of medicines 517\u003cbr\u003e\u003ci\u003eLiset van Dijk and Marcia Vervloet\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.7.6 Patient perspectives 525\u003cbr\u003e\u003ci\u003eJanine Traulsen and Janet Krska\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Drug utilization research around the world 535\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction to drug utilization research around the world 537\u003cbr\u003e\u003ci\u003eMonique Elseviers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.2 Drug utilization research in Africa 541\u003cbr\u003e\u003ci\u003eIlse Truter, Johanita Burger, and Joseph Fadare\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.3 Drug utilization research in the Eastern Mediterranean region 546\u003cbr\u003e\u003ci\u003eMamoon A. Aldeyab, Zainab Said Al-Hashimy, and Maha Talaat\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.4 Drug utilization research in South-East Asia 551\u003cbr\u003e\u003ci\u003eAnita Kotwani, Nithima Sumpradit, and Aminath Moomina\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.5 Drug utilization research in the Western Pacific Region 557\u003cbr\u003e\u003ci\u003eLisa G. Pont, Tuan Anh Nguyen, and Elizabeth Roughead\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.6 Drug utilization research in North America 563\u003cbr\u003e\u003ci\u003eJuan M. Hincapie-Castillo, Shawn Bugden, and Ingrid Sketris\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.7 Drug utilization research in South and Central America 569\u003cbr\u003e\u003ci\u003eClaudia Garcia Serpa Osorio-de-Castro, Luciane Cruz Lopes, and Carlos E. Durán\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.8 Drug utilization research in Europe 574\u003cbr\u003e\u003ci\u003eMarion Bennie, Lotte Rasmussen, and Janne Sepp\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.9 The Glasgow Declaration 580\u003cbr\u003e\u003ci\u003eMonique Elseviers, Björn Wettermark, Tanja Mueller, Anna Birna Almarsdottir, Ria Benkö, Marion Bennie, Irina Iaru, Katarina Gvozdanovic, Mikael Hoffmann, Verica Ivanovska, Seán MacBride-Stewart, Elisabetta Poluzzi, Lisa G. Pont, Hege Salvesen Blix, Gabriel Sanfelix-Gimeno, Gisbert W. Selke, Katja Taxis, Ana Tomas Petrovic, Indre Treciokiene, and Sabine Vogler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 583\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eEditors\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eMonique Elseviers, Björn Wettermark, Tanja Mueller, Ria Benkő, Marion Bennie, Katarina Gvozdanović, Mikael Hoffmann, Irina Iaru, Verica Ivanovska, Seán MacBride-Stewart, Elisabetta Poluzzi, Lisa Pont, Hege Salvesen Blix, Gabriel Sanfélix-Gimeno, Gisbert Selke, Katja Taxis, Ana Tomas Petrović, Indrė Trečiokienė, Sabine Vogler   \u003c\/p\u003e\u003cp\u003e\u003cb\u003eTowards a better understanding of how medicines are used in society\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eDrug Utilization Research (DUR) is a discipline which combines aspects of pharmacotherapy, epidemiology, and health services research into an interdisciplinary set of methods for analyzing and assessing the prescribing, dispensing and consumption of medicines. It combines both qualitative and quantitative approaches to facilitate the safe and effective use of pharmaceuticals. \u003ci\u003eDrug Utilization Research: Methods and Applications\u003c\/i\u003e provides a comprehensive introduction to this discipline, prepared by an international team of authors with broad experience in numerous fields. Now reorganized and updated to reflect the latest research and global challenges, it is an indispensable resource for understanding the use of pharmaceuticals. \u003c\/p\u003e\u003cp\u003eReaders of the second edition of \u003ci\u003eDrug Utilization Research\u003c\/i\u003e will find: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eNew chapters on methods, including more hands-on guidance on how to plan and conduct different types of drug utilization\u003c\/li\u003e\n\u003cli\u003eA section on specific applications in areas such as psychotropics, opioids, cancer drugs, antibacterials, and cardiovascular drugs\u003c\/li\u003e\n\u003cli\u003eA new section with case studies illustrating applications of DUR in different continents\u003c\/li\u003e\n\u003cli\u003eDetailed treatment of subjects including DUR and health policy, DUR in specific populations, and many more\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003e\u003ci\u003eDrug Utilization Research\u003c\/i\u003e is ideal for epidemiologists, pharmacists, physicians, nurses and others interested in drug use and its outcomes.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989088780517,"sku":"NP9781119911654","price":190.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119911654.jpg?v=1761782749","url":"https:\/\/k12savings.com\/es\/products\/drug-utilization-research-isbn-9781119911654","provider":"K12savings","version":"1.0","type":"link"}